Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Upgraded by Wedbush

Wedbush upgraded shares of Bicara Therapeutics (NASDAQ:BCAX) to a strong-buy rating in a research report report published on Wednesday,Zacks.com reports.

BCAX has been the subject of a number of other research reports. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective for the company. Cantor Fitzgerald initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. TD Cowen initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, HC Wainwright lifted their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $12.60 on Wednesday. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09. The stock’s fifty day moving average is $16.00.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Research analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Turn Management LLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $14,324,000. Geode Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $1,239,000. Vestal Point Capital LP purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $10,825,000. FMR LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Finally, Braidwell LP purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $42,219,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.